The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.
Novartis, in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm to help it gather and store patient data from medical devices.
At San Francisco's giant JP Morgan Healthcare Conference, tech company Qualcomm and Big Pharma player Novartis revealed a plan for a joint investment company with $100 million to spend on startups that "go beyond the pill."
Novartis has added another component to its "Clinical Trials of the Future" program. The latest element of the trial efficiency initiative sees the Swiss Big Pharma team up with computer chip maker Qualcomm to gather data on clinical trial participants between visits to the investigator site.
Novartis claims its Theraflu Multi-Symptom Severe Cold "starts to get to work in your body in 5 minutes" after taking it. But competitor Pfizer isn't having it--and neither is the National Advertising Division.
Novartis continues the protracted drawdown at its Diovan plant in New York, telling the state nearly two dozen more jobs will be whacked starting at the end of March.
Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug.
Novartis' Fluad influenza vaccine has been declared safe by another regulator, this time the European Medicines Agency, after being called into question following the deaths of patients in Italy who had been given the jab.
Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.
Italian authorities last week began recalling two lots of Novartis' influenza vaccine Fluad after more than a dozen deaths were reported in people who had taken the vaccine. But on Monday the Italian Pharmaceutical Agency cleared the manufacturing of the vaccines, saying that the initial analyses of the lots came back "negative."